- Home
- LX vs MOLN Comparison
LX vs MOLN Comparison
Compare LX & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | LX | MOLN |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | China | Switzerland |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.3M | 170.5M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LX | MOLN |
|---|---|---|
| Price | $0.71 | $3.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $2.13 | ★ $10.36 |
| AVG Volume (30 Days) | ★ 3.4M | 1.5K |
| Earning Date | 08-31-2026 | 10-29-2026 |
| Dividend Yield | ★ 53.02% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $450.00 |
| P/E Ratio | $2.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.71 | $3.53 |
| 52 Week High | $5.94 | $5.36 |
Technical Indicators
Market Signals| Indicator | LX | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 25.76 | 44.22 |
| Support Level | $0.71 | $3.79 |
| Resistance Level | $2.06 | $4.39 |
| Average True Range (ATR) | 0.04 | 0.13 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 16.67 | 16.49 |
Price Performance
Historical ComparisonAbout LX LexinFintech Holdings Ltd.
LexinFintech Holdings Ltd is an online consumer finance platform and a technology-driven service provider in China. The group is engaged in online direct sales services and online consumer finance services for its customers in the PRC. Geographically, it derives revenue from China.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.